Latest Morning Briefing Stories
Geographic, Racial Disparities In Stroke Treatment Tracked In New Study
Patients living in the Northeast are more than twice as likely to get a powerful drug than those in the Midwest or South and African-Americans were 26 percent less likely to get the medicine, a study in the journal Neurology finds.
Study: Health Spending Related To Opioid Treatment Rose More Than 1,300 Percent
Based on an analysis of insurance company payments, emergency room visits and lab tests were responsible for much of the overall spending.
Consumer Group Questions Role of Drug Costs In California Premium Hikes
Consumers Union says Anthem Inc. and Blue Shield of California may be exploiting furor over prescription drug prices. State regulators are looking into the issue.
Study Says Concerns About Orphan Drug Spending Are Unjustified
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.
EpiPen Controversy Fuels Concerns Over Generic Drug Approval Backlog
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.
Mylan’s Generic EpiPen — A Price Break Or Marketing Maneuver?
As news that Mylan will make available a generic version of its own brand-name product, KHN answers key questions about how this development could affect consumers.
Screening Positive For Depression Doesn’t Mean You’ll Get Treatment, Study Finds
A study in JAMA Internal Medicine suggests that patients known as the “worried well” are actually the highest utilizers of mental health care — and likely to receive antidepressants.
Government-Protected ‘Monopolies’ Drive Drug Prices Higher, Study Says
Researchers at Harvard University examined thousands of studies to determine why drug prices have climbed and what might be done about it.
California Lawmaker Pulls Plug On Drug Price Transparency Bill
The legislation would have required drug companies to notify the state and insurers about expensive new treatments or price hikes.
People With Obamacare Plans Filled More Prescriptions, But Had Lower Costs
A study explores how coverage gains resulting from the federal health law may have changed people’s health care habits and spending.
Fraud Concerns Emerge As Compounding Drug Sales Skyrocket
Federal spending has soared for drugs that are handmade in local pharmacies, and federal investigators are raising concerns about fraud or overbilling.
Busting Myths About Mental Illness
Mental illness is common — and so are misperceptions about it. These too-often-believed myths can be harmful to you and your loved ones.
Sounds Like A Good Idea? Regulating Drug Prices
Presidential candidates from both parties have proposals they say would help lower the cost of prescription drugs. But most experts say that efforts to regulate prices might not end up saving much money.
Medical Marijuana Linked To Modest Budget Benefits For Medicare Part D, Study Finds
A Health Affairs study determines that Part D spending went down slightly on prescription drugs for which medical marijuana is viewed as a possible alternative.
Study: Brand-Name Drugs’ High Copays Soak Medicare Part D Patients
A study in Health Affairs finds Medicare Part D beneficiaries were charged copays averaging 10.5 times more for Crestor and Nexium than generic drugs would have cost them.
Medicaid, Private Insurers Begin To Lift Curbs On Pricey Hepatitis C Drugs
Over the past few months, Massachusetts, Florida, New York, Delaware and Washington have lifted restrictions on the expensive medications, and private insurers around the country are also making the changes.
Anthem, Express Scripts Face Legal Challenge Over Prescription Drug Prices
The case alleges that insured consumers were overcharged because of a contract agreement.
California Drug Price Measure Fiercely Opposed By Pharmaceutical Industry
Proposed legislation would require drugmakers to disclose and justify price hikes. The industry has taken to Facebook and Twitter, warning that the proposal could lead to medication shortages in some regions of the state.
Filling A Prescription? You Might Be Better Off Paying Cash
Amid growing concern about rising drug costs, the practices of prescription benefit management firms are drawing a new level of attention.
Report From Key Calif. Agency Raises Concerns About Proposal To Cut Drug Prices
Staff researchers at California’s largest public buyer of health benefits say the goal of reducing drug costs for the state is appealing but might not work in the real world.
